Engineered FHL-1 Fusion Polypeptides for Complement and Lipid Control in AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for age-related macular degeneration (AMD), particularly dry AMD, are limited, and there is a need for treatments that can effectively address both dry and wet forms of the disease, as well as manage associated factors such as extracellular lipid deposits and retinal pigment epithelium disruption.
Innovation Solution
Engineered polypeptides comprising short consensus repeat regions of complement factor H (CFH) and Factor H-like protein 1 (FHL) peptides, with specific peptide sequences and linker domains, are developed to enhance complement inhibition and lipid regulation, which are administered via intraocular injection to treat AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If engineered polypeptides are designed to target multiple AMD pathways simultaneously, then therapeutic effectiveness is improved, but device complexity increases
Solution Approach 1:
The patent combines CFH SCR1-7 domain and FHL-1 SCR6-7 domain into a single fused polypeptide molecule (CFH-FHL peptide). This merging allows the therapeutic agent to simultaneously perform complement inhibition (via CFH domain) and proteoglycan/lipid regulation (via FHL-1 domain), thereby addressing multiple AMD pathological pathways with one agent rather than requiring separate therapies for each mechanism.
Solution Approach 2:
The engineered CFH-FHL polypeptide is designed to perform multiple functions: it inhibits complement activation, binds to proteoglycans in Bruch's membrane, and regulates lipid metabolism. This multi-functionality allows a single therapeutic agent to address the complex, multifactorial nature of AMD pathogenesis, including both wet and dry forms of the disease.
2Reliability
If specific peptide sequences are used to enhance binding activity, then proteoglycan binding is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies precise amino acid sequences for the CFH SCR1-7 domain (SEQ ID NO: 3) and FHL-1 SCR6-7 domain (SEQ ID NO: 17), along with defined linker regions (SEQ ID NOs: 11-16). These parameter specifications ensure optimal proteoglycan binding activity and complement inhibition while providing clear manufacturing targets for consistent production of the therapeutic polypeptide.
3Stability of the object's composition
If linker domains are optimized for protein stability, then polypeptide reliability is improved, but device complexity increases
Solution Approach 1:
The patent incorporates linker domains (SEQ ID NOs: 11-16) that serve as intermediary regions connecting the CFH SCR1-7 domain and FHL-1 SCR6-7 domain. These linkers act as flexible connectors that maintain proper spatial orientation and stability of the fused polypeptide while allowing each functional domain to operate independently, thereby ensuring overall protein stability without requiring complex structural arrangements.
Data Source
AI summary
An engineered polypeptide for use in treating age-related macular degeneration (AMD) comprising FHL-1 engineered variant peptides, compositions including these engineered polypeptides and methods of using them. Further, wherein polypeptides include a linker domain separating the first peptide sequence from the second peptide sequence, a first junction region between the first peptide sequence and the linker domain and a second junction region between the second peptide sequence and the linker domain.